You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
美国安进药厂19亿美元并购胃癌药研发商Five Prime
阿思达克 03-05 11:05
道指成分股,美国安进药厂(Amgen)(AMGN.US)以19亿美元收购Five Prime Therapeutics(FPRX.US),以扩大胃癌药研发。公司将透过是次收购,参与Five Prime Therapeutics的bemarituzumab胃癌药研发,该药已处最後临床测试阶段。公司亦同时取得bemarituzumab未来於中国销售的部分权益,因Five Prime Therapeutics与再鼎医药(09688.HK)就该药有市场推广及发展协议。

安进表示,该药除针对中国市场,在日韩及台湾市场亦有很大发展机会。

是次已非安进首度参与中国市场,安进於2019年以近30亿美元收购百济神州(06160.HK)20.5%股权。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account